Tumor specific novel taxoid-monoclonal antibody conjugates

Area of Science:

• Oncology
• Pharmacology
• Bioconjugation Chemistry

Background:

• Targeted drug delivery aims to improve cancer chemotherapy efficacy by conjugating drugs to tumor-specific molecules.
• Monoclonal antibodies (mAbs) offer high specificity for tumor antigens, making them suitable targeting agents.
• Paclitaxel, a vital chemotherapy drug, lacks tumor specificity, leading to systemic toxicity.

Purpose of the Study:

• To design and synthesize novel taxoid derivatives with enhanced cytotoxicity.
• To create targeted prodrugs by conjugating these taxoids to monoclonal antibodies (mAbs).
• To evaluate the in vivo antitumor activity and toxicity of these antibody-drug conjugates (ADCs).

Main Methods:

• Synthesis of new taxoids with methyldisulfanyl(alkanoyl) groups for improved cytotoxicity.
• Conjugation of a highly cytotoxic taxoid derivative to anti-EGFR monoclonal antibodies (mAbs).
• In vivo evaluation of the conjugates' efficacy and toxicity in EGFR-expressing A431 tumor xenografts in SCID mice.

Main Results:

• A novel, highly cytotoxic C-10 methyldisulfanyl-propanoyl taxoid was synthesized.
• EGFR-targeted antibody-taxoid conjugates were successfully prepared.
• Complete inhibition of tumor growth was observed in vivo in EGFR-expressing xenografts.
• No noticeable toxicity was detected in the treated animals.

Conclusions:

• The developed antibody-taxoid conjugates exhibit remarkable target-specific antitumor activity.
• This approach offers a promising strategy for enhancing cancer chemotherapy efficacy while minimizing side effects.
• Targeted delivery of potent taxoids via mAbs represents a viable therapeutic strategy for EGFR-expressing cancers.